CMA finds Actavis UK charged “excessive and unfair” prices
Drugmaker Actavis overcharged the UK’S national health service for hydrocortisone, a drug used to treat life-threatening conditions including Addison’s disease, the Competition and Markets Authority provisionally found today.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10